Holtackers, R. J., Van De Heyning, C. M., Nazir, M. S., Rashid, I., Ntalas, I., Rahman, H., Botnar, R. M., & Chiribiri, A. (2019). Clinical value of dark-blood late gadolinium enhancement cardiovascular magnetic resonance without additional magnetization preparation. *Journal of Cardiovascular Magnetic Resonance, 21*(1), [44]. https://doi.org/10.1186/s12968-019-0556-1
Clinical value of dark-blood late gadolinium enhancement cardiovascular magnetic resonance without additional magnetization preparation

Robert J. Holtackers¹,²,⁷†, Caroline M. Van De Heyning²,³,⁴,⁵†, Muhummad Sohaib Nazir²,³, Imran Rashid²,³, Ioannis Ntalas²,³, Haseeb Rahman²,³, René M. Botnar²,⁶ and Amedeo Chiribiri²*  

Abstract

Background: For two decades, bright-blood late gadolinium enhancement (LGE) cardiovascular magnetic resonance (CMR) has been considered the reference standard for the non-invasive assessment of myocardial viability. While bright-blood LGE can clearly distinguish areas of myocardial infarction from viable myocardium, it often suffers from poor scar-to-blood contrast, making subendocardial scar difficult to detect. Recently, we proposed a novel dark-blood LGE approach that increases scar-to-blood contrast and thereby improves subendocardial scar conspicuity. In the present study we sought to assess the clinical value of this novel approach in a large patient cohort with various non-congenital ischemic and non-ischemic cardiomyopathies on both 1.5 T and 3 T CMR scanners of different vendors.

Methods: Three hundred consecutive patients referred for clinical CMR were randomly assigned to a 1.5 T or 3 T scanner. An entire short-axis stack and multiple long-axis views were acquired using conventional phase sensitive inversion recovery (PSIR) LGE with TI set to null myocardium (bright-blood) and proposed PSIR LGE with TI set to null blood (dark-blood), in a randomized order. The bright-blood LGE and dark-blood LGE images were separated, anonymized, and interpreted in a random order at different time points by one of five independent observers. Each case was analyzed for the type of scar, per-segment transmurality, papillary muscle enhancement, overall image quality, observer confidence, and presence of right ventricular scar and intraventricular thrombus.

Results: Dark-blood LGE detected significantly more cases with ischemic scar compared to conventional bright-blood LGE (97 vs 89, \( p = 0.008 \)), on both 1.5 T and 3 T, and led to a significantly increased total scar burden (3.3 ± 2.4 vs 3.0 ± 2.3 standard AHA segments, \( p = 0.015 \)). Overall image quality significantly improved using dark-blood LGE compared to bright-blood LGE (81.3% vs 74.0% of all segments were of highest diagnostic quality, \( p = 0.006 \)). Furthermore, dark-blood LGE led to significantly higher observer confidence (confident in 84.2% vs 78.4%, \( p = 0.033 \)).

Conclusions: The improved detection of ischemic scar makes the proposed dark-blood LGE method a valuable diagnostic tool in the non-invasive assessment of myocardial scar. The applicability in routine clinical practice is further strengthened, as the present approach, in contrast to other recently proposed dark- and black-blood LGE techniques, is readily available without the need for scanner adjustments, extensive optimizations, or additional training.

Keywords: Late enhancement, Late gadolinium enhancement, LGE, Dark-blood, Myocardial scar, Subendocardial scar
Background
Although coronary artery disease related deaths have declined over the past 10 years, it remains the leading cause of death worldwide for both men and women [1]. Since survivors of previous myocardial infarction (MI) face an increased risk of new cardiovascular events, there is great focus on detecting and accurately assessing the infarcted region [2]. Important aspects of this assessment include determining the infarct’s location, size, and transmural extent. Over a decade ago it was first demonstrated that even small regions of MI were associated with large increases in major adverse cardiac events [3, 4], while regional functional recovery following revascularization was highly dependent on the transmural extent of the infarct [5–8]. It is clear that this information is an essential requisite for patient management decisions and selection of the optimal therapeutic approach.

Bright-blood late gadolinium enhancement (LGE) cardiovascular magnetic resonance (CMR) has been considered the reference standard in the non-invasive assessment of myocardial viability for almost two decades now. Its ability to clearly depict areas of myocardial infarction from viable myocardium is well established, making LGE a widely accepted component of standard clinical CMR protocols. By nulling the magnetization level of viable myocardium, its dark appearance can easily be distinguished from the bright appearance of scar tissue. However, as the adjacent LV blood pool can have similar T1 values at 10 min post-injection with almost equally bright signal, the border between scar and blood can be difficult to delineate. In particular patients with thin subendocardial scarring patterns in this border zone are susceptible to this limitation, where the apparent volume of scar tissue can be significantly reduced, or even completely obscured. Furthermore, blood pool signal can mimic scar tissue and lead to false positive observations. This makes subendocardial scar patterns difficult to detect and clearly delineate using conventional bright-blood LGE. Allowing additional time after contrast administration partly resolves this challenge, as due to contrast washout over time the scar and blood T1 values will start to diverge, thereby increasing scar-to-blood contrast. However, this solution is unfavourable in daily clinical practice, where already long CMR exams and blood T1 values will start to diverge, thereby increasing scar-to-blood contrast. However, this solution is unfavourable in daily clinical practice, where already long CMR exams are conducted. Extensive parameter optimizations and improving subendocardial scar conspicuity. However, as no additional magnetization preparation mechanisms are required, the novel approach is readily available in routine clinical setting without the need for scanner software adjustments, extensive parameter optimizations, and additional training.

Methods
Study population
A total of 300 consecutive patients referred for clinical CMR including LGE between March and September 2017 were included. Patients were randomly allocated to either a 1.5 T or 3 T clinical CMR scanner of different vendors: 1.5 T Ingenia (Philips Healthcare, Best, the Netherlands) \(n = 100\), 1.5 T Aera (Siemens Healthineers, Erlangen, Germany) \(n = 100\), and 3 T Achieva TX (Philips Healthcare) \(n = 100\). The study was approved by the local ethics committee (15/NS/0030) and was conducted according to the Declaration of Helsinki. Written informed consent was obtained from all patients for inclusion in the study and for additional CMR imaging during their clinical CMR exam.

LGE imaging
A routine clinical CMR protocol was used to obtain a cine stack of the short-axis view covering the entire left ventricle (LV) and right ventricle (RV) (10–15 slices), followed by cine images of the two-, three-, and four-chamber view. After an intravenous injection of 0.2 mmol/kg gadobutrol (Gadovist, Bayer, Berlin, Germany),
both conventional bright-blood LGE and proposed dark-blood LGE images were acquired in identical cardiac projections (full short-axis stack covering the entire LV and RV + three long-axis views). A 1:1 randomisation scheme was used to decide the order of acquisition of the LGE images. In 150 consecutive subjects (50 for each CMR scanner), conventional bright-blood LGE was performed first (starting at 10 min post-injection), followed by dark-blood LGE (starting at 20 min post-injection). In another 150 consecutive subjects (50 for each CMR scanner), the scans were acquired in reversed order: dark-blood LGE first (10 min post-injection), followed by conventional bright-blood LGE (20 min post-injection). The mechanism for the dark-blood LGE acquisition technique without using additional magnetization preparation has recently been described in detail [27]. Both methods used a PSIR acquisition and reconstruction, preceded by a Look-Locker sequence to determine the TI. For conventional bright-blood LGE, the TI was set to null viable LV myocardium, while for dark-blood LGE the TI was set to null the LV blood pool (Fig. 1), leading to a dark-gray appearance of the blood in the PSIR image. Specific sequence details for all three CMR scanners reflect the local clinical protocol and can be found in Table 1. Note that only the TI was adjusted in the local clinical protocols to acquire dark-blood LGE images. All images were acquired in the mid-diastolic resting period using 10–15 s breath-hold scans, depending on the subject’s heart rate. The given contrast dose reflects local protocol and current international guidelines [28].

Image analysis

The acquired image data of all subjects was randomly assigned for review to one of five independent level III trained observers blinded to subject characteristics. For each subject, the conventional bright-blood and dark-blood PSIR LGE images were separated, anonymized, and analyzed in random order at different time points. Thereby, the bright- and dark-blood LGE images of the same subject were never presented in sequence to the reader. The images were shown and interpreted according to the criteria recommended by the Society for Cardiovascular Magnetic Resonance (SCMR) [29]. All images were analysed using OsiriX v9.0 64-bit (Pixmeo, Geneva, Switzerland).

Overall image quality was rated on a four-point Likert scale for each method: 0) non-diagnostic, 1) low [≥ two segments non-diagnostic], 2) medium [one segment non-diagnostic], or 3) high [all segments correctly identified]. In case the image quality of either of the two methods was scored as 0 (non-diagnostic), the subject was excluded from further analysis. Subjects were classified with each LGE method as having: 0) no scar, 1) ischemic scar, 2) non-ischemic scar, or 3) both ischemic and non-ischemic LV scar. In case the classifications, as assigned by each method, did not match, consensus was provided by a level III observer with > 10 years of experience in CMR. In case any ischemic scar was observed, the entire short-axis stack was analyzed for maximum scar transmurality on a per-segment basis using the American Heart Association (AHA) model (17 segments). The transmural extent in each segment was evaluated as a percentage of the local total wall thickness using a five-point Likert scale: 0) no scar, 1) 1–25%, 2) 26–50%, 3) 51–75%, or 4) 76–100%. Total scar burden was calculated as the sum of all segments multiplied by their corresponding maximum transmurality percentage (maximum scar burden = 17). Observer confidence in scar detection and analysis was rated using a binary scale: 0) not confident or 1) confident. In addition, the presence of papillary muscle enhancement, RV scar, and LV thrombus was each assessed separately on a binary scale: 0) not present or 1) present. In a subgroup of 20 subjects, intra- and inter-observer agreement was assessed for both the presence of scar as well as total scar burden.

![Fig. 1 A series of short-axis images with varying inversion times (TI) (Look-Locker scan) in a subject with myocardial scar, acquired at ten minutes post-injection. The blood pool, viable myocardium, and myocardial scar each reach their own nulling point at different TIs. Note that for conventional bright-blood late gadolinium enhancement (LGE) the TI is set to null viable myocardium (blue arrow in frame 9, TI = 248 ms), while for dark-blood LGE the TI is set to null the blood pool (orange arrow in frame 5, TI = 150 ms)](image_url)
Statistical analysis

All statistical analyses were performed using SPSS Statistics 23 (Statistical Package for the Social Sciences (SPSS), International Business Machines, Inc., Armonk, New York, USA). Results are expressed as mean ± standard deviation or as percentage unless otherwise specified. Differences in the detection of myocardial scar between conventional bright-blood LGE and dark-blood LGE were evaluated using McNemar tests. Differences in total scar burden as assessed by both methods were evaluated using either the paired-sample t-test (normally distributed data) or the non-parametric Wilcoxon signed-rank test (non-normally distributed data). Normality of data was confirmed using the Shapiro-Wilk test. Differences in image quality and observer confidence between both methods were evaluated using a Wilcoxon signed-rank test and the McNemar test, respectively. Intra- and inter-observer variability in the presence of scar was assessed by calculating Cohen’s kappa and Fleiss’ kappa coefficients, respectively. Intra- and inter-observer variability in the total scar burden was assessed by calculating the intraclass correlation coefficient. Coefficients were considered: ‘poor’ < 0.40, ‘fair’ between 0.40 and 0.59, ‘good’ between 0.60 an 0.74, and ‘excellent’ > 0.75. All statistical tests were two-tailed and p-values < 0.05 were considered significant.

Results

Study population

Baseline characteristics of the study population are summarized in Table 2. Complete conventional bright-blood and dark-blood LGE data sets were acquired in all subjects (n = 300). Eight subjects (2.7%) had non-diagnostic image quality due to arrhythmia (n = 1), image artefacts (including respiratory motion, wrap-around, and shading) (n = 6), or a combination of both (n = 1), and were excluded from further analysis. Exclusion of these eight patients was caused by non-diagnostic image quality in the bright-blood LGE images only (n = 4), dark-blood LGE images only (n = 1), or both sets of images (n = 3). Statistical analysis was therefore performed on a population of 292 subjects. In total 4964 segments were analysed for LGE.

LV scar detection

An ischemic/subendocardial LV scar pattern was detected in 89 subjects by bright-blood LGE and in 97 subjects by dark-blood LGE (30.5% vs 33.2%, p = 0.008). All subjects with a definite diagnosis of ischemic scar on bright-blood LGE were also correctly identified by dark-blood LGE imaging (Figs. 2 and 3). However, eight subjects (8.3%) were declared free of any ischemic scar using conventional bright-blood LGE, but showed sub-endocardial enhancement using dark-blood LGE (Fig. 4). This effect was observed regardless of which sequence was acquired first (4 cases for each order of acquisition), and of the type of scanner used (Siemens 1.5T Aera: n = 1; Philips 1.5T Ingenia T: n = 4; Philips 3T Achieva: n = 3). Six out of these eight subjects were already known with ischemic heart disease (myocardial infarction [n = 2], previous percutaneous coronary intervention [n = 2], previous coronary artery bypass graft [n = 1], or a combination of myocardial infarction and revascularization [n = 1]). Total scar burden in subjects with ischemic scar was significantly higher on dark-blood LGE images compared to bright-blood LGE images (3.3 ± 2.4 vs 3.0 ± 2.3 standard AHA segments, p = 0.015; Figs. 5 and 6). Non-ischemic scar patterns were observed in 46 and 44 subjects with bright-blood LGE and dark-blood LGE, respectively (15.8% vs 15.1%). Although areas of non-ischemic scar were missed in two cases using dark-blood LGE in the present study (Fig. 7), interestingly, no cases of non-ischemic scar were missed when dark-blood LGE was performed at 10 min post-injection.

Detection of papillary muscle enhancement, RV scar, and areas of thrombus

Papillary muscle enhancement was detected in 17 (19.1%) subjects with ischemic scar using conventional bright-blood LGE and in 34 (35.1%) subjects with ischaemic scar using dark-blood LGE. RV infarction/fibrosis was detected in 6 and 7 cases using bright-blood LGE and dark-blood
Table 2 Baseline characteristics of study population (n = 300)

| Indicator | Value |
|-----------|-------|
| Age (years) | 55 ± 16 |
| Gender (male, %) | 179 (59.7%) |
| Weight (kg) | 83 ± 20 |
| Length (cm) | 171 ± 10 |
| BMI (kg/m²) | 28.2 ± 5.9 |
| BSA (m²) | 2.0 ± 0.3 |
| LVEDVi (mL/m²) | 92 ± 30 |
| LVESVi (mL/m²) | 48 ± 30 |
| LVEF (%) | 51 ± 14 |
| RVEF (%) | 55 ± 10 |
| Known significant CAD (n, %) | 68 (22.7%) |
| Previous myocardial infarction (n, %) | 48 (16.0%) |
| Previous PCI (n, %) | 32 (10.7%) |
| Previous CABG (n, %) | 10 (3.3%) |

Overall image quality

Overall image quality for the entire study population (n = 300) is illustrated in Fig. 8. Image quality was significantly better using dark-blood LGE than conventional bright-blood LGE (p = 0.006). All LV segments were of the highest diagnostic quality in 74.0% vs 81.3% of the subjects using conventional bright-blood and dark-blood LGE, respectively. Non-diagnostic image quality was observed in 7 (2.3%) and 4 (1.3%) cases using conventional bright-blood LGE and dark-blood LGE, respectively, which led to the exclusion of 8 cases in total. In the subgroup where dark-blood LGE was performed first at 10 min post-injection, no significant difference in overall image quality was found between the two methods (p = 0.563). However, when conventional bright-blood was performed first, dark-blood LGE showed significantly higher overall image quality (p = 0.002).

Observer confidence

Significantly higher observer confidence was found using dark-blood LGE compared to conventional bright-blood LGE (p = 0.033). Observers were confident in in 78.4% vs 84.2% of the subjects (n = 292) using conventional bright-blood and dark-blood LGE, respectively. In the subgroup where dark-blood LGE was performed first at 10 min post-injection, no significant difference in observer confidence was found between the two methods (p > 0.999). However, when conventional bright-blood was performed first, dark-blood LGE showed significantly higher observer confidence (p = 0.005).

Intra- and inter-observer agreement

Complete intra-observer agreement in the presence of scar was observed for both conventional bright-blood LGE and dark-blood LGE (κ = 1.00). For the inter-observer variability in the presence of scar, excellent agreement was found for both conventional bright-blood LGE (κ = 0.90) and dark-blood LGE (κ = 0.85). For the assessed total scar burden, excellent intra-observer agreement was found for both conventional bright-blood LGE (ICC = 0.95) and dark-blood LGE (ICC = 0.99). For the inter-observer variability in total scar burden, excellent agreement was found for both conventional bright-blood LGE (ICC = 0.77) and dark-blood LGE (ICC = 0.88).

Discussion

The aim of this study was to assess the clinical value of a novel dark-blood LGE approach, which does not require any additional magnetization preparation, in a large unselected cohort of 300 consecutive patients on multiple scanners with varying field strengths and from different vendors. This study shows that dark-blood LGE is more sensitive than conventional bright-blood LGE in the detection of ischemic scar, regardless of the field strength.
strength or scanner vendor, with higher average scar burden, increased overall image quality, and improved observer confidence. Dark-blood LGE led to the detection of ischemic scar patterns in subjects that were deemed free of scar by conventional bright-blood LGE, which has implications for patient management through the appropriate administration of secondary preventive therapies. Furthermore, no cases of LV thrombus were missed by dark-blood LGE in comparison to conventional bright-blood LGE.

Accurate subendocardial scar detection and delineation is crucial in patients with previous MI, as current treatment strategies are based on this assessment and the presence of even small areas of myocardial scar are
prognostically significant [3, 4]. Conventional bright-blood LGE using myocardium nulling is not always able to detect these areas immediately at 10 min after injection. As the contrast between subendocardial scar and the blood pool depends on a number of variables including gadolinium clearance, performing conventional bright-blood LGE later after contrast injection will readily increase subendocardial conspicuity [30]. However, even in the subgroup where bright-blood LGE was performed later and was expected to have superior contrast, dark-blood LGE (already performed at 10 min post-injection) showed increased subendocardial scar detection, potentially increasing the efficiency of clinical protocols.

Other solutions to improve scar-to-blood contrast for better subendocardial scar conspicuity include numerous recently proposed methods that use additional magnetization preparation mechanisms to suppress LV blood pool signal [18–26]. However, a potential disadvantage of these dark- and black-blood methods is the decrease in scar-to-myocardium contrast, potentially compromising the detection of non-ischemic scar compared to bright-blood LGE [31]. In contrast, dark-blood LGE without magnetization preparation would provide a larger contrast for the detection of subendocardial scars.

Fig. 4 Short-axis bright-blood and dark-blood LGE image of all eight discordant cases. Conventional bright-blood (upper row) and dark-blood (lower row) phase sensitive inversion recovery (PSIR) LGE short-axis images of all eight discordant cases. Areas of infarction are indicated by blue arrows. Note that these areas of infarction could have been recognized using conventional bright-blood LGE when the dark-blood images would have been shown simultaneously. However, when only the conventional bright-blood images were shown, these areas were missed and the patients were declared free of any ischemic scar, while dark-blood LGE showed clear hyperenhancement. Patient 2, 3, 4, 5, 6, and 8 had known coronary artery disease. In each patient, the yellow star indicates which method was performed first (at 10 min), while the two letters indicate the CMR system used for each study (see Table 1 for specific scan details, PI = Philips 1.5T Ingenia, SA = Siemens 1.5T Aera, PA = Philips 3T Achieva TX).

Fig. 5 Bright-blood and dark-blood LGE images of a subject with thin subendocardial infarction. Panel a: Conventional bright-blood phase sensitive inversion recovery (PSIR) LGE images of the short-axis at mid-ventricular level (SA), two-chamber view (2CH), three-chamber view (3CH), and four-chamber view (4CH), which show a possible subendocardial infarction in the LAD territory. The transmurality of the scar is not well defined. Panel b: Dark-blood PSIR LGE images of the same views reveal a 25% subendocardial myocardial infarction (blue arrows) in the septal segments and 25–50% transmurality in the apical lateral wall. Furthermore, the short-axis dark-blood LGE image shows enhancement of the anterolateral papillary muscle (orange arrow), which was not observed using conventional bright-blood LGE. In this case, conventional LGE and dark-blood LGE were performed at 20 min and 10 min post-injection, respectively. For specific scan details, see ‘Philips Ingenia’ at Table 1.
is able to maintain, or even exceed, the scar-to-myocardium contrast of conventional LGE, in addition to its superior scar-to-blood contrast [32].

Another important feature to consider when assessing the diagnostic capabilities of the proposed dark-blood LGE method is the accuracy of LV thrombus detection. Areas of LV thrombus can frequently be found in dysfunctional ventricles, most likely in correspondence with myocardial scar and wall motion abnormalities. When not identified and treated correctly, they can potentially result in life-threatening complications such as embolic myocardial infarction or cerebrovascular accident. As thrombus is characterized by its black appearance, conventional bright-blood LGE (or preferably early gadolinium enhancement) provides excellent contrast between the bright-blood and the black thrombus. Recently, various black-blood LGE approaches have been proposed that completely null the blood signal to improve subendocardial scar detection. As blood is rendered completely black using these sequences, thrombus may then seem to be part of the blood pool. However, by causing a dark-blood effect rather than a complete black-blood effect, blood will appear dark-gray and still allows the visualization of areas of thrombus with similar accuracy as conventional bright-blood LGE (Fig. 2) [27].

This study illustrated the clinical performance of a novel dark-blood LGE approach against conventional bright-blood LGE in a real-world situation. A large unselected cohort of 300 consecutive patients referred for clinical CMR including LGE was used, representing a typical everyday non-con genital case mix of ischemic and non-ischemic cardiomyopathies. The improved detection of ischemic scar, as well as the reliable detection of non-ischemic scar, RV scar, and LV thrombus, all achievable at 10 minutes post-injection, make the proposed dark-blood LGE method a viable and time-efficient alternative to conventional bright-blood LGE. These findings are of high applicability in most routine clinical settings, as the proposed dark-blood LGE approach, in contrast to other recently proposed dark- and black-blood techniques, is
readily available and does not require any scanner adjustments and/or extensive optimizations.

**Limitations**
Although the proposed dark-blood LGE method shows improved ischemic scar detection compared to conventional bright-blood LGE in a large cohort of patients, there was no histological confirmation. Importantly however, 75% of the subjects who showed an ischemic scar pattern on dark-blood LGE but not on bright-blood LGE, had known coronary artery disease that was related to the infarct territory. Whereas the authors feel the outcomes to be related to the proposed dark-blood LGE mechanism without using additional magnetization preparation, future studies that use histological validation in preclinical models would be of great value.

As the appearance of the conventional bright-blood and dark-blood LGE images are intrinsically different, full blinding for image type was impossible for this study. However, all LGE images were separated, anonymized, and analysed in random order at different time-points. Thereby, conventional bright-blood and dark-blood LGE images were never presented in sequence to the reader. Moreover, the readers were not informed of the aim of the study or of the technical details of the sequences acquired. Therefore, all readers were, as far as possible, blinded for image type in this study.

Although we also report on the detection of non-ischemic fibrosis, papillary muscle enhancement, RV fibrosis, and areas of LV thrombus, it should be stressed that the present study was not designed to draw any conclusions on these findings and therefore no $p$-values were provided. Moreover, as many discrete patterns of non-ischemic fibrosis are described in this general referral cohort, the present study would be underpowered to do so. As the quality of novel dark- and black-blood techniques is much debated for the detection of non-ischemic scar, future studies should focus on a comparison with conventional LGE regarding this type of scarring. Even though no conclusions are drawn on papillary muscle enhancement, the prevalence of papillary muscle enhancement in patients with MI in our study population is in agreement with values from previous literature [33].

Finally, signal threshold-based analyses have been used for LGE to delineate regions of scar. Exploring the impact of the dark-blood LGE approach used in the present study on signal threshold-based analyses was considered out-of-scope, but may be of interest for future studies.

**Conclusions**
Dark-blood LGE is more sensitive for the detection of ischemic scar than conventional bright-blood LGE, on both 1.5 T and 3 T MR scanners of different vendors, without compromising the detection of non-ischemic...
scar and areas of thrombus. Furthermore, dark-blood LGE showed higher average scar burden, increased overall image quality, and improved observer confidence. As all these features are already achievable at 10 minutes after contrast administration, this novel dark-blood LGE approach emerges as a valuable and time-efficient diagnostic tool in the non-invasive assessment of myocardial scar. The applicability in routine clinical practice is further strengthened, as this approach is readily available without the need for scanner adjustments and/or extensive optimizations.

Abbreviations

2CH: Two chamber; 3CH: Three chamber; 4CH: Four chamber; AHA: American Heart Association; ARVC: Arrhythmogenic right ventricular cardiomyopathy; CMR: Cardiovascular magnetic resonance; LAD: Left anterior descending; LGE: Late gadolinium enhancement; LV: Left ventricle/left ventricular; MI: Myocardial infarction; PSIR: Phase sensitive inversion recovery; RV: Right ventricle/right ventricular; SA: Short axis; SCMR: Society for Cardiovascular Magnetic Resonance; TI: Inversion time

Acknowledgements

The authors would like to thank the radiographers and administration team at King's College London and the Guy's and St Thomas' NHS Hospital Cardiac MRI Service for their cooperation and assistance during the imaging and administration processes. Dr. Michael Salerno served as a JCMR Guest Editor for this manuscript.

Authors' contributions

All authors made substantial intellectual contributions to the published study. RJH, CVDH, AC, RMB were responsible for the concept and design of this study. CVDH, MSN, IR, IN, HR, and AC collaborated in the data analysis, while all authors were responsible for data interpretation. All authors collaborated in writing the manuscript, revising it critically for important intellectual content, and gave final approval of this version to be published.

Funding

The authors acknowledge financial support from Stichting de Weijerhorst, the British Heart Foundation (RG/12/1/2262), the EPSRC (EP/P001009/1 and EP/P007619/1), the Welcome EPSRC Centre for Medical Engineering (NS/A000049/1 and WT/20148/2/16/2), the UK Medical Research Council (MR/P01979X/1), the FONDECYT Nº 1161051, the Department of Health through the National Institute for Health Research (NIHR) Healthcare Technology Cooperative for Cardiovascular Diseases at Guy's and St Thomas' Hospital, and the NIHR Biomedical Research Centre (BRC) awarded to Guy's & St Thomas' NHS Foundation Trust in partnership with King's College London. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, and/or the Department of Health.

Availability of data and materials

The acquired datasets used in this study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate

Participants provided written informed consent for the study inclusion and additional MR imaging during their clinical CMR exam. The study was conducted according to the Declaration of Helsinki and Good Clinical Practice guidelines, and was approved by the Guy's and St Thomas' Research Ethics Committee (approval number 15/NS/0030).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart disease and stroke statistics—2017 update: a report from the American Heart Association. Circulation. 2017;135:e146–603.
2. Kramer CM. The expanding prognostic role of late gadolinium enhanced cardiac magnetic resonance. J Am Coll Cardiol. 2006;48(10):1986–7.
3. Kwong RY, Chan AK, Brown KA, et al. Impact of unrecognized myocardial scar detected by cardiac magnetic resonance imaging on event-free survival in patients presenting with signs or symptoms of coronary artery disease. Circulation. 2006;113(23):2733–43.
4. Kwong RY, Sattar H, Wu H, et al. Incidence and prognostic implication of unrecognized myocardial scar characterized by cardiac magnetic resonance in diabetic patients without clinical evidence of myocardial infarction. Circulation. 2008;118(10):1011–20.
5. Pagley PR, Beller GA, Watson DD, Gimple LW, Ragosta M. Improved outcome after coronary bypass surgery in patients with ischemic cardiomyopathy and residual myocardial viability. Circulation. 1997;96(3):795–800.
6. C ̈ oral MF, Maddahi J, Rokhsar S, et al. Long-term survival of patients with coronary artery disease and left ventricular dysfunction: implications for the role of myocardial viability assessment in management decisions. J Thorac Cardiovasc Surg. 1998;116(6):997–1004.
7. Pagano D, Lewis ME, Townsend JD, Davies P, Camici PG, Bosner RS. Coronary revascularization for post ischemic heart failure: how myocardial viability affects survival. Heart. 1999;82(6):684–8.
8. Kim RJ, Wu E, Rafael A, et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med. 2000;343(20):1445–53.
9. Kim RJ, Fieno DS, Parish TB, et al. Relationship of MI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation. 1999;100(19):1992–2002.
10. Killman P, Ara AE, McVeigh ER, Aletas AH. Phase-sensitive inversion recovery for detecting myocardial infarction using gadolinium-delayed hyperenhancement. Magn Reson Med. 2002;47(2):372–83.
11. Aćakapya M, Rayazadeh H, Basha TA, et al. Accelerated late gadolinium enhancement cardiac MRI imaging with isotropic spatial resolution using compressed sensing: initial experience. Radiology. 2012;264(3):691–9.
12. Basha TA, Aćakapya M, Liev C, et al. Clinical performance of high-resolution late gadolinium enhancement imaging with compressed sensing. J Magn Reson Imaging. 2017;46(6):1829–38.
13. Liu H, Wilson GJ, Balu N, et al. 3D true-phase polarity recovery with independent phase estimation using three-tier stacks based region growing (3D-TRPS). MAGMA. 2018;31(1):87–99.
14. Shin T, Lustig M, Nishimura DG, Hu BS. Rapid single-breath-hold 3D late gadolinium enhancement cardiac MRI using a stack-of-spirals acquisition. J Magn Reson Imaging. 2014;40(6):1496–502.
15. Brati K, Henningsson M, Grigoratos C, et al. Image-navigated 3-dimensional late gadolinium enhancement cardiovascular magnetic resonance imaging: feasibility and initial clinical results. J Cardiovasc Magn Reson. 2017;19(1):97.
16. Menon RG, Miller GW, Jeudy J, Rajagopalan S, Shin T. Free breathing three-dimensional late gadolinium enhancement cardiovascular magnetic resonance using outer volume suppressed projection navigators. Magn Reson Med. 2017;77(4):1533–43.
17. Kellman P, Larson AC, Hsu LY, et al. Motion-corrected free-breathing delayed enhancement imaging of myocardial infarction. Magn Reson Med. 2005;53(1):194–200.
18. Kellman P, Chung YC, Simonetti OP, McVeigh ER, Arai AE. Multi-contrast delayed enhancement provides improved contrast between myocardial infarction and blood pool. J Magn Reson Imaging. 2005;22(5):605–13.
19. Liu C-Y, Wieben O, Brittain JH, Reeder SB. Improved delayed enhanced myocardial imaging with T2-prep inversion recovery magnetization preparation. J Magn Reson Imaging. 2008;28(5):1280–6.
20. Kellman P, Xue H, Olivieri LJ, et al. Dark blood late enhancement imaging. J Cardiovasc Magn Reson. 2016;18(1):77.
21. Basha TA, Tang MC, Tsao C, et al. Improved dark blood late gadolinium enhancement (DB-LGE) imaging using an optimized joint inversion preparation and T2 magnetization preparation. Magn Reson Med. 2018;79(1):51–60.
22. Fahmy AS, Neisius U, Tsao CW, et al. Gray blood late gadolinium enhancement cardiovascular magnetic resonance for improved detection of myocardial scar. J Cardiovasc Magn Reson. 2018;20(1):22.
23. Kim HW, Rehwald WG, Jenista ER, et al. Dark-blood delayed enhancement cardiac magnetic resonance of myocardial infarction. J Am Coll Cardiol Img. 2018;11(12):1758–69.
24. Muscogiuri G, Rehwald WG, Schoepf UJ, et al. TRAMINER) prepared imaging: a novel contrast-enhanced flow-independent dark-blood technique for the evaluation of myocardial late gadolinium enhancement in patients with myocardial infarction. J Magn Reson Imaging. 2017;45(5):1429–37.
25. Farrelly C, Rehwald W, Salemo M, et al. Improved detection of subendocardial hyperenhancement in myocardial infarction using dark blood-pool delayed enhancement MRI. Am J Roentgenol. 2011;196(2):339–48.
26. Peel SA, Morton G, Chiribiri A, Schuster A, Nagel E, Botnar RM. Dual inversion-recovery MR imaging sequence for reduced blood signal on late gadolinium-enhanced images of myocardial scar. Radiology. 2012;264(1):242–9.
27. Holtackers RJ, Chiribiri A, Schneider T, Higgins DM, Botnar RM. Dark-blood late gadolinium enhancement without additional magnetization preparation. J Cardiovasc Magn Reson. 2017;19(1):64.
28. Kramer CM, Barkhausen J, Flamm SD, Kim RJ, Nagel E. Standardized cardiovascular magnetic resonance (CMR) protocols 2013 update. J Cardiovasc Magn Reson. 2013;15:91.
29. Schulz-Menger J, Bluemke DA, Biemerich J, et al. Standardized image interpretation and post processing in cardiovascular magnetic resonance: Society for Cardiovascular Magnetic Resonance (SCMR) Board of Trustees Task Force on standardized post processing. J Cardiovasc Magn Reson. 2013;15(1):35.
30. Kellman P, Arai AE. Cardiac imaging techniques for physicians: late enhancement. J Magn Reson Imaging. 2012;36(3):529–42.
31. Francis R, Kellman P, Kotecha T, et al. Prospective comparison of novel dark blood late gadolinium enhancement with conventional bright blood imaging for the detection of scar. J Cardiovasc Magn Reson. 2017;19(1):91.
32. Foley JRI, Broadbent DA, Fent GJ, et al. Clinical evaluation of two dark blood methods of late gadolinium quantification of ischemic scar. J Magn Reson Imaging. 2019;50(1):146–52.
33. Aldrovandi A, De Ridder SJ, Strohm O, Cocker M, Sandonato R, Friedrich MG. Detection of papillary muscle infarction by late gadolinium enhancement: incremental value of short-inversion time vs. standard imaging. Eur Heart J Cardiovasc Imaging. 2013;14(5):405–9.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.